BioWorld News

This Pill Will Change Cancer Treatment Forever

New Research Reveals Exactly How Doctors Treat Men and Women Differently

Updated: Electra says $350M IPO will help it become a commercial biotech

How Sleepy Dogs and Collapsing Mice Taught Scientists About Narcolepsy

A transplanted pig kidney buys time for a human one to become available

Personalized mRNA cancer vaccines offer new hope. We explain

The Definition for a Heart Attack Just Changed—and It Could Help Women in a Big Way

Novartis inks $3.2B subcutaneous delivery deal with Alteogen

Scientists design new RNA therapy to bypass mutations behind thousands of genetic diseases

FDA approves Otsuka’s ADHD drug Simtriyo, teeing up its ‘next major CNS launch’

The FDA has granted approval to Otsuka for Simtriyo, marking the introduction of the first triple reuptake inhibitor for the treatment of ADHD.

MapLight shares sink on mixed ph. 2 schizophrenia readout

7 news sources are covering this Business story right now — Newsylist is tracking how fast it spreads.

Ahead of hearing, FDA questions the efficacy of Capricor’s Duchenne drug

Capricor Therapeutics shares have plunged after FDA staff raised concerns regarding the efficacy and data of its Duchenne heart disease therapy.

An HIV vaccine is within reach thanks to mRNA

5 news sources are covering this Health story right now — Newsylist is tracking how fast it spreads.

New study untangles how Epstein-Barr viral infection triggers immune response in multiple sclerosis

The F.D.A. Approves a New Pill to Slash Cholesterol Levels

The FDA has approved Lipfendra, the first-of-its-kind oral PCSK9 inhibitor designed to significantly reduce cholesterol levels.

Biologists pinpoint how common virus triggers multiple sclerosis

7 news sources are covering this Health story right now — Newsylist is tracking how fast it spreads.

While Musk's Neuralink drills into skulls, China's BrainCo bets the future of brain tech is wearable

A growing divide in the brain-computer interface market pits surgical implants against non-invasive wearable technology.

Lab-grown retinal cells show promise for new eye therapies

Dual tumour–myeloid targeting of glioblastoma with GPNMB CAR-T cells

Researchers are testing a dual-targeting GPNMB CAR-T cell therapy to treat aggressive glioblastoma and its supporting immune cells.

Medical Journal Retracts Study Claiming Cancer Therapy Is More Effective When Given in the Morning